Skloots, Collins and More on Henrietta Lacks' Cell Line Deal

More details about the unprecedented
arrangement involving Henrietta Lacks' cell line emerged today in a
wide range of publications, including a Nature journal piece that
said it was not a precedent.
The article was co-authored by Francis
Collins
, head of the NIH, and Kathy Hudson, deputy director for
science, outreach and policy at the NIH.

“It is important to note, however,
that we are responding to an extraordinary situation here, not
setting a precedent for research with previously stored,
de-identified specimens. The approach we have developed through
working with the Lacks family is unique because HeLa cells were taken
and used without consent, and gave rise to the most widely used human
cell line in the world, and because the family members are known by
name to millions of people.”

The restrictions on use of the cell
lines came about after a flap erupted about their recent use without
the knowledge of her descendants. (The California Stem Cell Report carried a commentary on it yesterday.) Rebecca Skloots, author of the
best-seller, “The Immortal Life of Henrietta Lacks,” wrote about
the controversy in a March 23 op-ed piece in the New York Times. She
said,
In the article, Skloots said,

“Imagine if someone secretly sent
samples of your DNA to one of many companies that promise to tell you
what your genes say about you. That report would list the good news
(you’ll probably live to be 100) and the not-so-good news (you’ll
most likely develop Alzheimer’s, bipolar disorder and maybe
alcoholism). Now imagine they posted your genetic information online,
with your name on it. Some people may not mind. But I assure you,
many do: genetic information can be stigmatizing, and while it’s
illegal for employers or health insurance providers to discriminate
based on that information, this is not true for life insurance,
disability coverage or long-term care.

“'That is private family
information,” said Jeri Lacks-Whye, Lacks’s granddaughter. “It
shouldn’t have been published without our consent.'”

Nature also carried a Q&A with Collins in which he said,

“This has wrapped in it science,
scientific history, ethical concerns, the bringing together of people
of very different cultures, a family with all the complications that
families have.”

In the Wall Street Journal this
morning, Ron Winslow described the arrangement with the NIH like
this.

“Under the pact, two descendants of
Ms. Lacks will serve on a six-member panel with scientists to review
proposals from researchers seeking to sequence the DNA of cell lines
derived from her tumor or to use DNA profiles of such cells in their
research. That gives family members a highly unusual voice in who
gets access to personal health information.

Terms call for controlled access to the
genomic data and credit to the Lacks family in papers and scientific
presentations based on the research done with the DNA data.”

In an interview in The Scientist,
Skloots, who was involved in the Lacks-NIH negotiations, said the
Lacks family asked for her participation.

“The only reason I was involved in
this is because scientists did this without the family’s consent
and then it got all of this press coverage, and no one asked the
question, 'Did the family give consent?' So I sort of waded back
in.”

She continued, 

“That OpEd that I
wrote was the first time I’d ever publicly expressed an opinion,
which was, 'Really?!? Are we going to continue to not ask the Lacks
family questions?' I was kind of shocked in a sense that nobody
thought to raise that issue.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/7XRzMDgIWjo/skloots-collins-and-more-on-henrietta.html

'Paradigm Shift' — Researchers as Patient Advocates?

It is not easy for a stem cell
scientist to break into “print” in that bastion of American
capitalism, Forbes magazine. Much less one from that perceived
antithesis of free enterprise, Reed College.
But researcher Paul Knoepfler of UC
Davis
has done just that.
John Farrell of Forbes wrote about Knoepfler on
Friday in the wake of the announcement Knoepfler will be honored with
a “national advocacy” award by the Genetics Policy Institute.
Paul Knoepfler -- Advocate for a "new ethos"
UC Davis photo
Knoepfler, who received a degree in
English literature from Reed in 1989, is being recognized for his
activities as a stem cell blogger since 2009.
Farrell quoted Knoepfler as saying in
an email,

“With many stumbles, face plants,
land mines, and even a few threats of litigation and career
retaliation along the way for the last three and half a years, I
turned my crazy idea into a reality.”

Farrell continued,

“But it was only possible,
(Knoepfler) added, with guidance from many patient advocates and
bloggers in other fields who generously helped him learn the ropes of
blogging.

“'I see this award as a validation of
the notion that advocacy by scientists has become a valued part of
the stem cell field,' he said.

“'My hope is to catalyze a continuing
paradigm shift whereby stem cell scientists and biomedical scientists
more generally have a new ethos that not just accepts, but also
deeply values advocacy.'”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tuEB7SGOuMQ/paradigm-shift-researchers-as-patient.html

California Stem Cell Official Duane Roth in Improving Condition

Duane Roth, the co-vice chairman of the
California stem cell agency, is improving after he was hospitalized
for treatment of a serious brain injury sustained in a bicycle accident Sunday in
the mountains east of San Diego.
According to a report on Xconomy.com,
Roth's brother, Ted, said yesterday, 

“Were certainly moving in the
right direction. We're now looking at the recovery phase.”

The article by Bruce Bigelow said Roth
has passed through the most critical period following surgery at the
UC San Diego hospital.
Roth, the 63-year-old CEO of the San
Diego technology organization, Connect, is in serious condition in a
medically induced coma.
The governing board of the California
stem cell agency yesterday took special note of Roth at its meeting and sent its best wishes to him and his family.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/nmnYkisG6MU/california-stem-cell-official-duane.html

California Stem Cell Agency Looking for New Home in Two Years

The California stem cell agency is located south of Market Street in San
 Francisco, close to the San Francisco Giants ballpark(upper right).  Since
 the agency has been there, the area has grown from seedy to gentrified. 
Some not-so-good news surfaced today in
San Francisco involving the $3 billion California stem cell agency.
The news has little to do with its
science efforts but everything to do with where it is located and its
overhead expenses. The agency will be forced out of its free office
space – 20,000 square feet – in two years. The free space was
provided under an $18 million recruitment package and is worth at
least $1 million a year, according to the agency's auditors.
The bad news is that the San Francisco
office-space market is sizzling hot. Google, Yahoo, Microsoft and
other technology firms are scrambling for space in
Baghdad-by-the-Bay, as the city is sometimes known. According to a story this morning by James Temple in the San Francisco Chronicle,
the firms are looking for a total of about 800,000 square feet and
are prepared to pay well for it.
One nearly completed deal involving
Yahoo would cost about $48 per square foot for a 10-year lease. If
CIRM paid at that rate, it would have nearly $1 million in additional
costs annually. However, leasing rates are expected to rise substantially in the next year or so. Also involved in a move would
be the cost of parking, which could run about $360,000 a year.
The stem cell agency is already
examining its options for new offices, including some sort of special
deal with the City of San Francisco.
Former State Sen. Art Torres, onetime
chairman of the state Democratic Party and co-vice chairman of CIRM,
briefed agency directors on the matter at its meeting in May. He
said,

“I met with the mayor of San
Francisco(Ed Lee), who's a dear friend, and he encouraged us to be
aware that he's very committed to helping us find some space in San
Francisco. Whether it means tax credits or incentives to a potential
landlord, we still have to work that out. Obviously we still have to
work out what the space will be. But the fact that the mayor has
indicated very explicitly that he wants to keep us in San Francisco,
I think it will bode well for us down the road.

“The current owner of the property
(Stockbridge Capital Partners) has not been happy that for ten years
they've had to supply free rent to us. And what they didn't
anticipate was having to provide for over $755,000 in operating
costs, which they thought some donors would take are of. Those donors
-- some of whom passed away and others who chose to give money to
other institutions, UC San Francisco, in particular, to the stem cell
lab, which was very much appreciated, I know, by UCSF – but at
the end of the day, there's no room for negotiations with this
current owner.”

CIRM Director Joan Samuelson asked
Torres whether future rent would also be free. Torres, who is also
president of San Francisco's Public Utilities Commission, replied,

“I would not work on that assumption.
I would work on the assumption somewhere between a dollar and more,
again, dependent upon what kind of tax incentives the City of San
Francisco would provide. We're very fortunate that my son(Joaquin
Torres
) is the deputy mayor for economic development, so we also have
him working on this as well.”

Samuelson replied,

“I'll ask more questions offline.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/v8usDDMWucE/california-stem-cell-agency-looking-for.html

CIRM's Roth Dies Following Bike Accident

Duane Roth, co-vice chairman of the
California stem cell agency, died yesterday from brain injuries
suffered in a bicycle accident two weeks ago.
Duane Roth, Connect photo

Roth, CEO of Connect, a San Diego
organization aimed at fostering technology entrepreneurship,
succumbed yesterday afternoon at the UC San Diego Medical Center, the
San Diego U-T
reported. He was 63.
An avid bicyclist, Roth was injured
while biking in the mountains east of San Diego July 21. Roth hit an
outcropping and his helmet was broken in the accident.
Roth was a long-time member of the
29-person governing board of the $3 billion California stem cell
agency and was a strong advocate for industry. He chaired the
agency's loan task force, was vice chair of the Intellectual Property
and Industry Engagement Subcommittee
and a member of the executive
committee.
J.T. Thomas, chairman of the stem cell
agency, released the following statement this morning.

“On behalf of all the CIRM family, we
mourn the loss of our colleague and dear friend Duane Roth. 
Throughout his tenure with us, he was one of the true stewards of the
mission, offering countless insights on the role of industry in the
world of regenerative medicine and how best and efficiently to drive
therapies through to patients.  He was unfailingly a voice of
reason and optimism and always sought to find ways to make things
happen, refusing to take 'no' for an answer.  Though one of 29
Board members, his extensive participation as co-Vice Chair of the
Board, co-chair of Intellectual Property and Industry Engagement
Subcommittee and a member of our Executive Committee gave Duane a
singularly important and resonant voice in our organization. 
His passing will be deeply felt by all of us as well as by the many
patients and other CIRM stakeholders whom he touched over the years. 
We send our deepest sympathies to Renee, Duane's brothers and the
rest of the Roth family.”

Roth recently was involved in raising
funds for cancer, and reporter Bradley Fikes wrote in the San Diego
U-T,

“Contributions in Roth’s name can
be made to Pedal
the Cause
, a fund-raiser for cancer research that Roth supported.
More than $10,000 has been raised since Roth's accident."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/58gRzPR09kU/cirms-roth-dies-following-bike-accident.html

California Stem Cell Agency Launches $70 Million Alpha Stem Cell Clinic Project

The California stem cell agency today approved
a $70 million plan to create a network of “Alpha” stem cell
clinics that is aimed at making the Golden State one of the leading
purveyors and developers of stem cell therapies in the world.

The 29-member governing board of the California
Institute for Regenerative Medicine (CIRM)
adopted the plan on a 19-1 vote. The negative vote came from Joan Samuelson, who questioned
whether the plan was premature and whether existing scientific research justified development of the clinics. 
Sherry Lansing, a patient advocate board member and
former head of a Hollywood studio, said the proposal is “one of the
most exciting proposals that we have ever had in front of us.” She
said it was the “beginning of this dream coming true.”
Under the far-reaching proposal, which
CIRM President Alan Trounson has been promoting for two years, the
agency will finance five stem cell clinics at established
institutions in California with grants of up to $11 million. Another
$15 million will be allotted for a stem cell information and
coordination center. Major matching contributions will be expected
from award winners over the five-year terms of the grants.
The effort is aimed at drawing in
clinical trials and patients from the around the world and creating a
central bank of knowledge, know-how and regulatory expertise. It
will also guide efforts to build profits into stem cell therapies
and to develop strategies to attract investors and philanthropists.
(For more information on the plan, see here, here, here, here and
here.)
Trounson said in a statement,

“These clinics have the potential to
revolutionize how we deliver stem cell therapies to patients. Stem
cell therapies are a completely new way of treating diseases and
disorders so we need a completely new way of delivering those in a
safe and effective manner. These clinics will help us do just that
and the clinical trials carried out in this network will fulfill the
agency’s promise of bringing new therapies to patients who need
them.” 

The journal Nature Medicine has
reported that the Alpha clinics would be the first-ever “clinical
trials network focused around a broad therapeutic platform.”
The CIRM board heard no negative
comment on the plan other than the remarks by Samuelson. . However,
not everyone sees a need for it. Mahendra Rao, director of the Center
for Regenerative Medicine
 at the National Institutes of
Health(NIH)
, says its surveys of researchers have not shown a demand
for such centers. In May, a researcher at institution that likely
would be an applicant filed a blistering, anonymous comment on the
California Stem Cell Report, describing it as a "boondoggle" and "irresponsible." The scientist said,

“Another boondoggle for some medical
schools but made to order for private operators like for-profit
cancer, dialysis, and laser eye specialty clinics that do one
procedure.  I can see each of the medical schools gifted with
one as they each were gifted with about 25 million dollars for stem
cell institute buildings.”

The researcher continued,

“The NIH at various times has tried
to organize clinical trials groups with infrastructure, like quick
reaction forces, ready to gear up for a new trial at the drop of a
hat. They mainly did nothing but suck money, kept staff employed,
because there are generally few drugs ready for early human trials
and each treatment that is brought along requires a unique contract,
ethics reviews, and different facilities, equipment and staff than
planned for.  The latest incarnation are CTSAs or CTSIs,
clinical and translational science centers funded by the federal NIH
that most if not all California medical schools already have.”

The RFA for the proposal is expected to
go out in October and approval of funding coming one year from now. Here is the link to today's CIRM press release on the plan. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/EBbBzLL9dQQ/california-stem-cell-launches-70.html

Another $23 Million to Recruit Star Stem Cell Scientists to California

California's $46 million effort to lure
stem cell research stars to the Golden State was expanded today by
another $23 million.
Directors of the stem cell agency
approved the funds on a 14-4-1 vote. CIRM directors Jeff Sheehy and
Francisco Prieto were among those opposing the move. Prieto declared,

“We are coming up against finite resources. We have better ways to spend
our money."

 Sheehy said that CIRM is contributing to inflation in stem cell science with its lucrative recruitment grants. 

Those supporting the expansion said that the grants have had a great impact on the field, not only bringing in individual scientists, but accompanying researchers in their labs along with grants from other sources.
The additional funds will go to
institutions that have not already benefited from one of the earlier
grants in the program. Up to four awards are expected to be made.
The CIRM staff proposal on the plan
said,

“A number of California institutions
have not yet been able to secure a confirmed Research Leadership
award but would benefit greatly from the recruitment of emerging or
established leaders in stem cell biology. Participation in the CIRM
program could bring additional, exceptional researchers to
California, strengthen and synergize with other efforts to build up
local sustained research communities in stem cell biology and
medicine and provide ongoing leadership at the cutting edge of
California regenerative medicine.”

All of the California institutions
involved with the winning researchers have representatives on the
governing board of the stem cell agency. They are not allowed, however, to vote
on grants to their institutions or researchers -- only on proposals such as today's $23 expansion.
Applications are due in January with
final approval scheduled for next May. The program is not open to
businesses.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iJ66PTxTsX8/another-23-million-to-recruit-star-stem.html

Stem Cell Lines and Paid-for Eggs: Stem Cell Agency Delays Action on Easing Restrictions

A key panel of the California stem cell
agency today balked at approving a plan to ease restrictions on
using stem cell lines derived from women who were paid for their
eggs.
The proposal had been scheduled to be
taken up tomorrow by the governing board of the $3 billion agency,
but the board's standards working group delayed action.
In response to a question, Kevin
McCormack
, a spokesman for the agency, said in an email,

“It was felt that more discussion
was needed before moving to a vote so another meeting is going to be
scheduled.”

In 2006, the CIRM governing board
approved regulations that banned the use of CIRM funds for stem cells
lines derived using compensation. That rule would be modified under
today's plan, which would permit the CIRM governing board to approve
the use of such lines following a staff study evaluating scientific and ethical issues.
Their use would be allowed if the lines would “advance CIRM's
mission.”

The delay came after four
organizations, including the Center for Genetics and Society in
Berkeley, argued that the plan is vague and did not adequately
address safety issues.
The four-page statement by the groups
said that the plan does not appear to have met “numerous concerns”
raised in 2009 in a document co-authored by the CIRM staff. Those
concerns include long-term risk and ethical issues.
Under the proposal, the groups said
that the agency governing board

“...will decide whether to approve a
grantee’s request to use a stem cell line created with paid-for
eggs on the basis of whether doing so 'will advance CIRM’s
mission.' This criterion is much too vague, and doesn’t include
consideration of the health or welfare of the women who undergo egg
retrieval. Protecting the well-being of women providing eggs is not
even mentioned (though perhaps it could be considered as an element
of the fifth of five 'factors to be considered by the ICOC(the agency
board),' 'whether the donation…was consistent with `best practices’
at the time of donation').”

The standards group also heard from a
UCLA researcher who argued on behalf of the change. Kathrin Plath
said she and her colleagues wanted to use a paid-for stem cell line
from the Oregon experiment that cloned human stem cells.

(An earlier version of this item said the change under consideration would ease restrictions on "purchasing" stem cell lines. The word "purchasing" was changed to "using.")
Here is the text of the statement by
the four organizations.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/QECOGHuAvIc/stem-cell-lines-and-paid-for-eggs-stem.html

$70 Million Alpha Stem Cell Clinic Project Garners Mainstream Media Attention

California's $70 million plan for a
chain of “Alpha” stem cell clinics today received its first major
attention from the mainstream media.
The story came in the state's largest
circulation newspaper, appearing this morning on the home page of the
website of Los Angeles Times.
The Alpha project would create five clinics
around the state and a coordination/information center under a
concept that comes before the governing board of the state's $3
billion stem cell agency at its meeting tomorrow in Burlingame, Ca. Funds could be
awarded as early as a year from now. (For more information, see here
and here.)
Reporter Eryn Brown quoted Natalie
DeWitt
, special projects officer for CIRM, as the stem cell agency is known, and Maria Millan, a CIRM
medical officer. Brown wrote,

“Clinics to conduct trials of stem
cell therapies have different needs than clinics designed to deliver
conventional therapies, DeWitt and Millan said. They need special
facilities for handling the cells safely, as well as imaging
equipment to track the cells once they're delivered into a patient’s
body.  Some of this infrastructure already exists, but other
parts of it still need to be perfected.  Establishing clinics to
house multiple trials might create the critical mass needed to get
the infrastructure in place, they said....

"Additionally, they said, CIRM
hopes that such collaboration would encourage stem cell companies to
share information -- speeding their own work and also helping out
policymakers and insurers who are trying to figure out how they'll
pay for stem cell therapies in the future.”

The Times quoted the
California Stem Cell Report as saying last week,

 “The Alpha clinics
are aimed at creation of a sturdy foundation for the stem cell
industry in California, capitalizing on the burgeoning, international
lure of stem cell treatments.”

The proposal envisions Alpha stem cell
clinics at major, established institutions around the state. It is
possible that two could be located in the Los Angeles area at
institutions such as UCLA, USC, Cedars-Sinai or the City of Hope, all
of which have representatives on the stem cell agency's governing
board. Other likely locations are in the San Francisco Bay area and
San Diego, again at facilities such as Stanford, UC San Francisco and
UC San Diego that have representation on the agency board.

Institutions competing for the grants,
including businesses, will be subject to closed-door. peer review
prior to final action by the full governing board.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/s_-mm4nTU_0/70-million-alpha-stem-cell-clinic.html

Paying for Human Eggs, Ivan Illich and Jerry Brown

California's pay-for-eggs bill is
stalled in a technical parliamentary process as opponents continue to
wage their campaign urging Gov. Jerry Brown to veto the proposal,
which swept easily through the legislature.
The latest volley against the
industry-sponsored measure appeared this week as an op-ed in The Sacramento Bee. The legislation would allow women to be paid for eggs for scientific research. The op-ed piece invoked the philosopher Ivan Illich, a
longtime friend of Jerry Brown and much respected by him.
Written by Diane Tober and Nancy
Scheper-Hughes
of the Center for Genetics and Society of Berkeley,
the July 16 article said,

“The late historian of science and
technology, Ivan Illich, warned against the processes of medical
industries which 'create new needs and control their satisfaction and
turn human beings and their creativity into objects.'"

The op-ed said,

“Women's research eggs (have) become
the hot new bio-product, increasing the profits of the
multibillion-dollar-per-year infertility industry at the expense of
women's health, safety and possibly, their future fertility. Is this
the 'equity' we want for ourselves, our sisters and our daughters?”

In 2003, Brown wrote a remembrance of
Illich, whom he first met in 1976. Brown said that Illich

“...bore witness to the destructive
power of modern institutions that 'create needs faster than they can
create satisfaction, and in the process of trying to meet the needs
they generate, they consume the earth.'”

The egg compensation bill (AB926 by
Assemblywoman Susan Bonilla, D-Concord) would remove a ban in
California on paying women who provide their eggs for scientific
research. Currently women who provide eggs for fertility purposes can
be paid, sometimes as much as $50,000, depending on the
characteristics of the woman providing the eggs. The bill would not
alter the ban on using research funds from the California stem cell
agency to pay for eggs. However, the agency next week will consider a proposal to allow use of agency funds to purchase stem cell lines
derived from eggs through compensation. (For
more information
on
the bill
,
see 
here, here and here.)
The egg bill received final legislative
approval on July 1. The governor has 12 days to act on the measure
once it actually reaches his desk. However, as of this morning, the
legislation remained in what is known as the “engrossing and
enrolling” process. It could be a routine delay but the process can
also be used to manage the flow of legislation to the governor. Brown
is currently on a two-week trip to Germany and Ireland and is not
expected to return until near the first of August.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/emjwUNr50p4/paying-for-human-eggs-ivan-illich-and.html

UCLA Researcher Calls for Easing of Restrictions on Stem Cell Lines Derived from Eggs From Paid Providers

A UCLA researcher has spoken out in
support of a proposal to allow use of California stem cell agency
funds to purchase stem cell lines derived from eggs provided by women
who have been paid for the service.
Kathrin Plath, an associate professor, said in a letter to the agency that she and her colleagues would like to use a line from the Oregon SCNT
experiment by Shoukhrat Mitalipov in which human stem cells were cloned. Currently agency funds cannot be used for that purpose as
a result of regulations that are the extension of a state law that
bars use of agency funds for payment for eggs.
The agency's standards group meets later today to consider changing those regulations. The proposal will
then go before the full board tomorrow.
Plath, who has received $5 million from CIRM, said,

“In my lab, we are ... interested in
understanding what happens to the somatically silenced X chromosome
when differentiated cells are reprogrammed by SCNT. The key question
is: are these SCNT-ESCs more similar to iPSCs or
fertilization-derived ESCs with respect to the epigenetic state of
the X chromosome. Furthermore, it has been shown in mouse
reprogramming that the active X chromosome becomes deregulated during
SCNT-based reprogramming, and we would like to address this problem
in the human system as well.

“We believe that the comparison of
the epigenetic states between fertilization-derived ESCs, SCNT-ESCs
and human iPSCs is important for a better characterization of these
cells and understanding of their epigenetic nature.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/2YTtgbJCtRw/ucla-researcher-calls-for-easing-of.html

Shestack Resignation Letter: Heartfelt and Eloquent

Jon Shestack(l) with J.T. Thomas, chairman of
CIRM, at a 2012 board meeting
California Stem Cell Report photo
Patient advocate Jon Shestack , who
resigned this week as a director of the
California stem cell agency, was on board on Day One in December 2004
when the agency's work began with no offices, no desks, no chairs, no phones and
no ability to even write checks.
Shestack's appointment came as a result
of his work in the autism community. He and his wife, Portia Iversen,
founded Cure Autism Now in 1995. A Hollywood film producer, Shestack
rattled cages at CIRM from time to time during his eight years of
service. And earlier this week, he wrote a heartfelt, eloquent
resignation letter, which he provided to the California Stem Cell
Report.
The full text can be found below. Here are some excerpts.

“Over eight years there were moments
that were inspiring, some were contentious, and there was a bruising
number of meetings but through it all, the board was involved,
passionate and, will forever be for me, the gold standard when it
comes to integrity.
“The same goes double for the staff –
truly the most excellent, devoted, committed group of people I
have ever had the pleasure of working with.”

“When I started at CIRM, my sweet son
with autism was 12. Now he is 21. Over eight years our family has
learned more about how many are the challenges that await him and how
few the opportunities he has to look forward to. We have seen his
world get smaller and smaller. While my son is special to me. He is
not unique. There are thousands and thousands affected by mental
illness who need a better life.
“Sometimes feel that I have failed
these people, in particular those affected by autism or cerebral
palsy. Though CIRM ran first-rate workshops on these disorders, we
did not do all we could to follow up, put out disease-specific RFAs
and get in proposals that addressed the workshop recommendations. I
wish I had been more persuasive."

“In the movies, the third act is
where the hero takes stock of all the previous wins and losses, all
the hardships and lessons learned, and she puts all that knowledge
together in new, and surprising ways until victory is within reach!
As CIRM enters its third act, I hope it will do the same. I hope it
will challenge itself, always put the urgency of the mission
ahead of everything else and be willing to question the policies that
have been so successful in the past, and consider that new ones may
be needed for the future.
“And this is the future as I see it
for CIRM. We will have faith, but we will continue to earn our
miracles We will use our hearts and our minds to rip those miracles
out of the dreamy future and make them real today. We will seek out
the best scientists and encourage them to use all their wisdom, art
and discernment to bring us cures. And when we have done that, we
will do it again the next day. We will be optimistic, but not
satisfied. We will question authority, despise complacency and above
all love those among us in need of healing--this is the obligation
without end, whose reward is also without end.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/BaaZlqP9Q4s/shestack-resignation-letter-heartfelt.html

California Stem Cell Agency to Commit 20 Percent of Remaining Cash

The California stem cell agency next
Thursday is expected to move forward with plans to give away $128
million, roughly 20 percent of its remaining funds.
The programs include the $70 million Alpha clinic plan, an ambitious five-year project that would be one
of the $3 billion agency's hallmark efforts. The other “concept”
rounds up next week include a $35 million “tools and technology”RFA and $23 million to recruit four more star, stem cell scientists to California.
The agency has committed about $1.8
billion of its $3 billion so far with about $700 million available
for future spending. The remainder is going for the agency's
administrative expenses. Cash for new grants is expected to run out
sometime in 2017. Total cost of the agency's efforts run to about $6
billion because it operates with money borrowed by the state and must
pay interest.
The agency is currently engaged in
developing a plan to develop new sources of funding with an eye on
some sort of public-private model. It solicited proposals in May for
help with the effort, with the goal of completing a plan by this
fall. At last report, however, the contract with the consultant had
not been let.
The “strategic roadmap,” as it is
called, is likely to come up at next week's governing board meeting
along with a review of agency goals for the 2013-14 fiscal year.
On the agenda is a proposal to modify the agency's ban on use of its funds to purchase stem cell lines derived from human eggs supplied by women who have been paid. That proposal will
also be heard by the agency's standards group next Wednesday.
The agency has additionally been busy
implementing recommendations from a performance audit in May 2012.
The audit said the agency was laboring under a range of problems that
include protection of its intellectual property and management of its
nearly 500 grants plus an inadequate ability to track its own
performance. A staff Power Point presentation seems to indicate that it is making substantial progress in solving the problems identified by the audit.
Next week's meeting will be in
Burlingame near the San Francisco Airport. Two remote locations where
the public can participate are also available in Los Angeles.
Addresses can be found on the agenda.

The California Stem Cell Report will
provide live coverage of the meeting based on the Internet audiocast
with stories filed as warranted.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8Zu2WtPeFrI/california-stem-cell-agency-to-commit.html

Veto Campaign Launched on California Pay-For-Eggs Bill

Opponents of the California
pay-for-eggs bill have kicked off a campaign to urge Gov. Jerry Brown to veto the industry-backed legislation.
The Center for Genetics and Society of
Berkeley yesterday posted a pitch on its website urging readers to
contact the governor's office by email, fax, phone or letter. The
target is a bill that would remove the ban in California on paying
women for their eggs for stem cell and other scientific research.
Women can already be paid for their eggs for fertility purposes.
Diane Tober, associate executive
director of the center, wrote,

“If you agree that more research on
short- and long-term risks is needed before expanding the market for
women’s eggs, please act quickly. Contact Governor Brown and ask
him to veto AB926.”

Also making the same pitch is the
Alliance for Humane Biology, another San Francisco Bay area
organization.
The bill, AB926 by Assemblywoman Susan
Bonilla
, D-Concord, has literally been cloaked in motherhood/reproductive issues. The measure has easily swept through the legislature and is now on its
way to the governor. The bill is sponsored by the AssociationFew if any stem cell or other research
organizations have been heard from during hearings on the bill. (For
more information, see here, here and here.)
However, stem cell scientists have
complained in past years about the lack of eggs for research,
declaring that women want to be paid.
The measure would not affect the ban on
compensation for eggs in research funded by the $3 billion California
stem cell agency. However, the agency on July 24 will consider providing exceptions for stem cell lines derived from eggs that
involve compensation for women.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/OqoMeSiIO_c/veto-campaign-launched-on-california.html

Sacramento Mental Health Advocate Appointed to Stem Cell Agency Board

Al Rowlett
Turning Point photo
Sacramento mental health advocate Al
Rowlett
has been named to the governing board of the $3 billion
California stem cell agency, it was announced today.
Rowlett replaces Jonathan Shestack on
the 29-member panel. Shestack had served on the board since 2004,
when the agency was created by the Proposition 71 ballot initiative.
Rowlett is chief operating officer of Turning Point Community Programs in Sacramento. He was appointed to
the CIRM board by California Assembly Speaker John Perez, D-Los
Angeles. Rowlett will fill one of the 10 patient advocate slots on
the board. He will be only African-American on the panel. The board
had also included one African-American, Ted Love, from 2004 to April
2012, when Love resigned.
Rowlett is no stranger to public and
governmental service. He is in his second term as a member of the Elk
Grove school board
, the fifth largest school district in California.
He has worked for Turning Point since 1981.
CIRM's press release said Rowlett also
serves on several other boards including Child Abuse Prevention
Center, California Institute of Mental Health
and is a commissioner
for the United States Psychiatric Rehabilitation Association
Certification Program.
In 2007, Rowlett won the National Association
of Social Work- California and California State University – Heart
of Social Work Award
and the Asian Pacific Community Counseling –
Inspirational Mental Health Leadership Award.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/C2aH568yoco/sacramento-mental-health-advocate.html

TV News Piece on Pay-for-Eggs Airs in Los Angeles, San Francisco

The California pay-for-eggs legislation
yesterday picked up some mainstream media coverage, including a
two-minute, 24-second segment on two major television stations in Los
Angeles and San Francisco.
The piece stands out because the
mainstream media has largely ignored the bill, with a couple of
exceptions. The piece is also exceptional because it appeared on TV
news, which reaches many more people than print media.
Nannette Miranda, Sacramento bureau
chief for KABC-TV in Los
Angeles, KGTV in
San Diego, KGO-TV in San
Francisco and KFSN-TV in Fresno, prepared the segment, which included on-camera interviews with both
supporters and opponents. The video appeared on KGO and KABC
and may well appear later on the other stations. It can be seen at
the end of this item.
The legislation, AB926 by Susan
Bonilla
, D-Concord, would remove the ban in California on paying
women for their eggs for stem cell and other scientific research.
Women can already be paid for their eggs for fertility purposes.
Another piece on the bill appeared in
another mainstream media outlet this morning, the San Diego U-T.
Writing in an op-ed column, Leah Campbell said she sold her eggs at
age 25 and has since become infertile as the result of problems her
doctors believe involved the process of providing the eggs.

“Six months (after providing the
eggs) my body began to fail me. I had always been a healthy and
active woman, but suddenly I was crippled by pain and unable to live
the life I had once enjoyed. I was soon diagnosed with stage IV
endometriosis, a disease my doctors now believe was pushed into
overdrive as a result of the potent hormones involved in my egg
donation protocols.”

Campbell continued,

“AB 926 may open the doors for
increased fertility research, but the potential costs for women’s
lives and health far outweigh any compensation that could ever be
offered.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/uMnWUVrymr8/tv-news-piece-on-pay-for-eggs-airs-in.html

California Stem Cell Merger: Capricor and Niles Therapeutics

Capricor, Inc., a Beverly Hills company
benefiting from $27 million from the California stem cell agency,
this week announced that it is merging with Niles Therapeutic, Inc.,
of San Mateo.
Linda Marban
Capricor photo
The Capricor story and its treatment
for heart disease have been highlighted (see here and here) by the $3
billion state research agency, which is partially funding a clinical
trial for the firm. The firm sprang from work by Eduardo Marban of
Cedars-Sinai in Los Angeles, one of Capricor's founders. He received
$6.9 million for his early and current work. Capricor was awarded
$19.8 million more.
Capricor, a privately held firm, and
the publicly traded Niles announced on Monday that they were merging.
The new company will be known as Capricor Therapeutics, Inc., and will
be based in San Mateo.
The new firm will be publicly traded
with Capricor CEO Linda Marban as the new CEO.
The new board of directors will have
two members from Niles and seven from Capricor, including its
executive chairman, Frank Litvack, who was an unsuccessful candidate for chairman of the stem cell agency board in 2011.
The merger press release said that the
new company “should
have better access to capital, more potential for steady pipeline
development and more risk diversification."
On completion of the merger, a joint
press release said,

Nile
will issue to Capricor stockholders shares of Nile common stock such
that Capricor stockholders will own approximately 90% of the combined
company's outstanding shares, and Nile stockholders will own
approximately 10%, calculated in each case on a fully-diluted basis
assuming the issuance of shares underlying options and warrants.
Options of Capricor will be assumed by Nile and become options to
acquire stock of Nile.”

Linda Marban said,

"Capricor's
and Nile's product portfolios complement each other well, as our
therapies will address both the underlying causes and debilitating
effects of heart disease. Capricor's CDCs are allogeneic cardiac
derived stem cells that aim to attenuate and potentially improve
damage to the heart that can result in heart failure, while Nile's
cenderitide is intended to treat patients following hospital
discharge from an acute episode of heart failure."

Niles' stock price stood at $0.04
recently. Its 52 week high was $0.20 and the 52-week low was $0.02.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/qqVK630tSl0/california-stem-cell-merger-capricor.html

Pay-for-Eggs Legislation: Strange Bedfellows and Existential Questions

 The California pay-for-eggs bill
today generated a feature article that said the legislation has
“sparked an unusual lineup of partisans on both sides and resonates
far beyond” the Golden State.
The piece by Alex Mathews on Capitol
Weekly
, a news service specializing in California government and
political coverage, said,

“(C)omplicating the issue is
California’s role as a national leader in stem cell research, the
existential question of who or what constitutes a research subject,
and finally, the fact that compensation for fertility purposes is and
has been legal for years in California.”

Mathews was writing about the measure
(AB926) by Assemblywoman Susan Bonilla, D-Concord, that removes a ban
in California on paying women for eggs for scientific research.
Currently women can be paid in California for providing eggs for IVF.
The measure would not alter a ban on compensation for eggs in
research financed by the $3 billion California stem cell agency.
However, later this month, the agency will consider modifying its position somewhat.
The bill has passed the legislature and
is on its way to Gov. Jerry Brown. The industry association
sponsoring the bill expects the governor to sign it later this month
although the governor, as a general rule, does not make public
commitments on legislation.
Mathews' article covered the background
and arguments on the bill and noted that it has received little
mainstream media attention.
Lisa Ikemoto
UC Davis photo
She also quoted Lisa Ikemoto, a law
professor and bioethicist at UC Davis, on the sensitive nature of the
issue. Ikemoto said,

“On the fertility side, it’s
politically hard to touch because it’s all around family formation.
Nobody wants to restrict family formation. On the research side, when
the issue of payment for eggs came up, it was connected with human
embryonic stem cell research, and human embryonic stem cell research
was politicized from the outset.”

Mathews also wrote about the strange
bedfellows opposing the bill. She said,

“Groups that fundamentally oppose
stem cell research such as the California Catholic Conference and
other pro-life groups are natural opponents of the bill, but they are
joined by a number of pro-choice groups who expressed concerns over
the limited research on the effects of egg donation on women’s
health.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/pskHpPceyco/pay-for-eggs-legislation-strange.html

Coming Up: Live Coverage of Today's California Stem Cell Meeting

The California Stem Cell Report will
provide live, wall-to-wall coverage of today's meeting of the
governing board of the $3 billion California stem cell agency.
At the top of the agenda is a $70
million proposal aimed at creating a string of Alpha stem cell clinics in
California that would serve as a foundation for the state's stem cell
business. Also on tap are other proposed grant programs, including a
$23 million expansion of a researcher recruitment effort and a $35 million round aimed at removing roadblocks to turning research into
cures.
Stories will be filed as warranted
throughout the day based on the Internet audiocast of the proceedings. 

Interested parties can also listen in
on the meeting via the Internet. Instructions can be found on the agenda.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Vi8IGlL2TzY/coming-up-live-coverage-of-todays.html

Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments

The California stem cell agency is
moving to remove an absolute ban on use of stem cell lines derived
from eggs from women who have been paid to provide them.
The action comes as state legislation
is headed for Gov. Jerry Brown's desk that would permit payments for
eggs to be used in research that is not funded by the agency. The measure (AB926) would not alter the separate ban on egg payments
involving research funded by the $3 billion stem cell agency.
Under a proposal that will come before the agency's standards group July 24, CIRM's governing board could
approve the use of stem cell lines derived as a result of payment to
women. Board action would be based on whether stem cell lines would
“advance CIRM's mission” and would follow a staff evaluation
involving scientific and ethical issues.
Over recent years, stem cell
researchers around the country have reported that they are not able
to obtain sufficient eggs without payment. And earlier this year,
paid egg providers were used in research in Oregon that cloned human stem cells, a feat that researchers have struggled with for years.
A CIRM staff report said that the
Oregon research has “generated scientific interest among CIRM
grantees and the desire to utilize derived SCNT lines. CIRM’s
current policy prohibits the use of the (Oregon) SCNT lines because
oocyte donors were financially compensated. CIRM requests the Medical
and Ethical Standards Working Group (SWG) revaluate this prohibition
with regard to CIRM grantees ability to utilize the resulting lines
in light of recent scientific and policy developments.”
Last month, the California Stem Cell
Report
queried the agency concerning earlier, sketchy information onthe CIRM blog about a possible change in its compensation rules. We
asked whether the agency was considering “sidestepping” the ban
on compensation. Kevin McCormack, a CIRM spokesman, said, “No, not
at all.” He said it would be premature to elaborate until a firm
proposal was ready.
The staff proposal to be considered on
July 24 said,

“Proposition 71’s 'prohibition on
compensation' compels the ICOC(the agency's governing board) to adopt
standards 'prohibiting compensation to research donors.' This
requirement has been consistently interpreted to prohibit the use of
CIRM funds to financially compensate oocyte (or other cell or tissue)
donors. In 2006, this interpretation was extended to exclude from
use, in CIRM-funded research, any stem cell line where research
donors were financially compensated, even if the derivation was done
without the use of CIRM funds. Proposition 71, however, does not
compel the ICOC (the agency's governing board) to prohibit the use of
stem cell lines where financial compensation is provided to the
oocyte donors, provided that CIRM funds are not used to compensate
the donors or derive the lines.”

The July 24 meeting will be held in San
Francisco. No remote teleconference locations have been announced.  If approved, the changes would likely be considered July 25 by the full agency board.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/BF3kpSRnKXQ/eggs-and-cash-stem-cell-agency.html